About-cancer / lapaʻau / clinical-hoʻokolohua / testicular-cancer
Nā ho'āʻo hoʻokolohua e mālama ai i ka maʻi ʻaʻai Testicular
Nā hoʻāʻo 1-4 o 4
ʻO Nivolumab a me Ipilimumab i ka mālama ʻana i nā mea maʻi me nā tumors liʻiliʻi
ʻO kēia pae II hoʻokolohua hoʻopaʻa haʻawina nivolumab a me ipilimumab i ka mālama ʻana i nā mea maʻi me nā tumors laha ʻole. Hiki i ka Immunotherapy me nā monoclonal antibodies, e like me ka nivolumab a me ka ipilimumab, ke kōkua i ka ʻōnaehana pale o ke kino e hoʻouka i ka maʻi ʻaʻai, a e hoʻopilikia paha i ka hiki ke ulu a pālahalaha nā pūnaewele tumora. Hoʻokomo kēia hoʻokolokolo i nā mea komo aku no kēia mau cohort e pili ana i ke ʻano: 1. Epithelial tumors of nasal cavity, sinuses, nasopharynx: A , and squamous cell carcinoma o ke poʻo a me ka ʻāʻī [SCCHN]) B) Adenocarcinoma a me nā ʻano like ʻole o ka puka ihu, sinus, a me nasopharynx (pani ʻia i ka accrual 07/27/2018) 2. Epithelial tumors of major salivary glands (closed to accrual 03 / 20/2018) 3. ʻO nā tumors type gland salivary o ke poʻo a me ka ʻāʻī, lehelehe, esophagus, ʻōpū, trachea a me ka akemāmā, ka umauma a me nā wahi ʻē aʻe (pani ʻia i ka accrual) 4. Ka maʻi kanesa ʻole o ka gastrointestinal (GI) ʻāpana 5. Adenocarcinoma me nā ʻano o ka ʻōpū liʻiliʻi (pani ʻia i ka ʻohi 05/10/2018) 6. ʻO ka maʻi kanesa liʻiliʻi me nā ʻano like ʻole o ke kahawai GI (ʻōpū ʻōpū ʻōpū, kolona, ka pololei, pancreas) (pani ʻia i ka accrual 10/17/2018) 7. Fibromixoma a me ka adenocarcinoma mucous papa haʻahaʻa (pseudomixoma peritonei) o ka pākuʻi a me ka ovary (pani ʻia i ka accrual 03/20/2018) 8. Laʻi ʻole nā tumere pancreatic me ka acinar cell carcinoma, cystadenocarcinoma mucous a i ʻole cystadenocarcinoma serous. ʻAʻole kūpono ka pancreatic adenocarcinoma 9. Intrahepatic cholangiocarcinoma (pani ʻia i ka accrual 03/20/2018) 10. Extrahepatic cholangiocarcinoma and bile duct tumors (pani ʻia i ka accrual 03/20/2018) 11. Sarcomatoid carcinoma of lung 12. Bronchoalveolar carcinoma lung. Kapa ʻia kēia ʻano i kēia manawa he adenocarcinoma in situ, adenocarcinoma invasive minimally, lepidic predominant adenocarcinoma, a i ʻole invasive mucinous adenocarcinoma 13. Non-epithelial tumors of the ovary: A) Germ cell tumor of ovary B) Mullerian huikau tumor a me adenosarcoma (pani i ka accrual 03/30/2018) 14. Tumo Trophoblastic: A) Choriocarcinoma (pani ʻia i ka accrual) 15. ʻO ke kinetona cell transitional ʻē aʻe ma mua o ka renal, pelvis, ureter, a i ʻole bladder (pani ʻia i ka accrual) nā ho'āʻo a me nā tumors germ extragonadal: A) Seminoma a me nā maʻi kanesa testicular B) Non-seminomatous tumor C) Teratoma me ka hoʻololi malignant (pani ʻia i accrual) 17.
Kahi: 895 mau wahi
ʻO ka nānā ʻana i ka hana, Bleomycin, Carboplatin, Etoposide, a i ʻole Cisplatin i ka mālama ʻana i nā Pediatric a me nā maʻi o nā mākua me nā Tumors Cell Germ. ʻO kēia mahele o ka hoʻāʻo ʻana e nānā pono i ka nānā pono ʻana, ka bleomycin, ka carboplatin, ka etoposide, a i ʻole ka cisplatin e hana ai i ka mālama ʻana i nā pediatric a me nā mea maʻi makua me nā ʻōpala cell germ. . Hiki ke kōkua i ka nānā ʻana i nā kauka e nānā i nā kumuhana me nā tumors germ germ liʻiliʻi ma hope o ka hemo ʻana o kā lākou tumo. ʻO nā lāʻau i hoʻohana ʻia i ka chemotherapy, e like me bleomycin, carboplatin, etoposide, a me cisplatin, hana i nā ala like ʻole e hōʻoki ai i ka ulu ʻana o nā hunaola tumora, ma ka luku ʻana paha i nā hunaola, ma ke kāpae ʻana iā lākou mai ka hoʻokaʻawale ʻana, a i ʻole ke kāpae ʻana iā lākou mai ka hoʻolaha ʻana. Kahi: 460 mau wahi
ʻO Inotuzumab Ozogamicin a me ka Chemotherapy Post-Induction i ka mālama ʻana i nā mea maʻi me ka B-ALL kiʻekiʻe loa, i hui pū ʻia me Phenotype Acute Leukemia, a me B-LLy
Ke aʻo nei kēia pae III inā inotuzumab ozogamicin i hoʻohui ʻia i ka chemotherapy post-induction no nā mea maʻi me ka High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) hoʻomaikaʻi i nā hopena. Ke aʻo pū nei kēia hoʻokolokolo i nā hopena o nā mea maʻi me ka phenotype huʻi leukemia (MPAL), a me ka B-lymphoblastic lymphoma (B-LLy) ke mālama ʻia me nā lāʻau ALL me ka ʻole o ka inotuzumab ozogamicin. ʻO Inotuzumab ozogamicin kahi antibody monoclonal, i kapa ʻia ʻo inotuzumab, i hoʻopili ʻia i kahi ʻano chemotherapy i kapa ʻia ʻo calicheamicin. Hoʻopili ʻo Inotuzumab i nā hunaola maʻi ʻaʻai i kahi ala i kuhi ʻia a hāʻawi i ka calicheamicin e pepehi iā lākou. ʻO nā lāʻau ʻē aʻe i hoʻohana ʻia i ka regima chemotherapy, e like me cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, merc laptopurine, prednisone, thioguanine, vincristine, a hana ka pegaspargase i nā ala like ʻole e hōʻoki i ka ulu ʻana o nā hunaola maʻi ʻaʻai, a i ʻole ma ka luku ʻana i nā hunaola, ma ke kāpae ʻana iā lākou mai ka hoʻokaʻawale ʻana, a i ʻole ke kāpae ʻana iā lākou mai ka hoʻolaha ʻana. E aʻo pū kēia hoʻokolokolo i nā hopena o nā mea maʻi me ka phenotype huʻi leukemia (MPAL) a hoʻolaha ʻia ʻo lymphoblastic lymphoma (B-LLy) ke mālama ʻia me ka nui o ka chemotherapy ALL. ʻO ka pahuhopu nui o kēia noi ʻana e hoʻomaopopo inā hoʻohui ka inotuzumab ozogamicin i ka maʻamau o ka mālama ʻana i ka chemotherapy a hoʻomaikaʻi paha i nā hopena ma High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). ʻO ka ʻāpana mua o ke aʻo ʻana e pili ana i nā ʻelua mau mua o ka hoʻoponopono ʻana: Induction a Consolidation. E hōʻiliʻili kēia ʻāpana i ka ʻike e pili ana i ka leukemia, a me nā hopena o ka mālama mua ʻana, i mea e hoʻokaʻawale ai i nā mea maʻi i nā hui lapaʻau ma hope o ka hoʻohui ʻana. Ma ka ʻāpana ʻelua o kēia noi ʻana, e loaʻa i nā mea maʻi ke koena o nā pōpō chemotherapy (mālama mau au I, hoʻolohi i ka hana, mālama mau II, mālama), me kekahi mau mea maʻi e loaʻa ʻole ka inotuzumab. ʻO nā pahuhopu ʻē aʻe o kēia noi me ka ʻimi ʻana inā mālama i nā kāne a me nā wahine me ka lōʻihi like o ka chemotherapy e mālama i nā hopena no nā kāne i mālama mua ʻia no kahi makahiki hou aku e hoʻohālikelike ʻia me nā kaikamahine, a me ka loiloi i nā ala maikaʻi e kōkua ai i nā mea maʻi e pili i ka waha. regimens chemotherapy. ʻO ka mea hope loa, ʻo kēia noiʻi ka mea mua e nānā i nā hopena o nā kumuhana me ka Lybhoblastic Leukemia B-cell i hoʻolaha ʻia (B LLy) a i ʻole Mixed Phenotype Acute Leukemia (MPAL) ke mālama ʻia me ka chemotherapy B-ALL. e loaʻa i nā mea maʻi ke koena o nā pōpō chemotherapy (mālama mau manawa I, hoʻolōʻihi i ka hana, mālama mau II, mālama), me kekahi mau mea maʻi i loaʻa ʻole i inotuzumab. ʻO nā pahuhopu ʻē aʻe o kēia noi me ka ʻimi ʻana inā mālama i nā kāne a me nā wahine me ka lōʻihi like o ka chemotherapy e mālama i nā hopena no nā kāne i mālama mua ʻia no kahi makahiki hou aku e hoʻohālikelike ʻia me nā kaikamahine, a me ka loiloi i nā ala maikaʻi e kōkua ai i nā mea maʻi e pili i ka waha. regimens chemotherapy. ʻO ka mea hope loa, ʻo kēia noiʻi ka mea mua e nānā i nā hopena o nā kumuhana me ka Lybhoblastic Leukemia B-cell i hoʻolaha ʻia (B LLy) a i ʻole Mixed Phenotype Acute Leukemia (MPAL) ke mālama ʻia me ka chemotherapy B-ALL. e loaʻa i nā mea maʻi ke koena o nā pōpō chemotherapy (mālama mau manawa I, hoʻolōʻihi i ka hana, mālama mau II, mālama), me kekahi mau mea maʻi i loaʻa ʻole i inotuzumab. ʻO nā pahuhopu ʻē aʻe o kēia noi me ka ʻimi ʻana inā mālama i nā kāne a me nā wahine me ka lōʻihi like o ka chemotherapy e mālama i nā hopena no nā kāne i mālama mua ʻia no kahi makahiki hou aku e hoʻohālikelike ʻia me nā kaikamahine, a me ka loiloi i nā ala maikaʻi e kōkua ai i nā mea maʻi e pili i ka waha. regimens chemotherapy. ʻO ka mea hope loa, ʻo kēia noiʻi ka mea mua e nānā i nā hopena o nā kumuhana me ka Lybhoblastic Leukemia B-cell i hoʻolaha ʻia (B LLy) a i ʻole Mixed Phenotype Acute Leukemia (MPAL) ke mālama ʻia me ka chemotherapy B-ALL. ʻO nā pahuhopu ʻē aʻe o kēia noi me ka ʻimi ʻana inā mālama i nā kāne a me nā wahine me ka lōʻihi like o ka chemotherapy e mālama i nā hopena no nā kāne i mālama mua ʻia no kahi makahiki hou aku e hoʻohālikelike ʻia me nā kaikamahine, a me ka loiloi i nā ala maikaʻi e kōkua ai i nā mea maʻi e pili i ka waha. regimens chemotherapy. ʻO ka mea hope loa, ʻo kēia noiʻi ka mea mua e nānā i nā hopena o nā kumuhana me ka Lybhoblastic Leukemia B-cell i hoʻolaha ʻia (B LLy) a i ʻole Mixed Phenotype Acute Leukemia (MPAL) ke mālama ʻia me ka chemotherapy B-ALL. ʻO nā pahuhopu ʻē aʻe o kēia noi me ka ʻimi ʻana inā mālama i nā kāne a me nā wahine me ka lōʻihi like o ka chemotherapy e mālama i nā hopena no nā kāne i mālama mua ʻia no kahi makahiki hou aku e hoʻohālikelike ʻia me nā kaikamahine, a me ka loiloi i nā ala maikaʻi e kōkua ai i nā mea maʻi e pili i ka waha. regimens chemotherapy. ʻO ka mea hope loa, ʻo kēia noi ka mea mua e nānā i nā hopena o nā kumuhana me ka Lybhoblastic Leukemia B-cell i hoʻolaha ʻia (B LLy) a i ʻole Mixed Phenotype Acute Leukemia (MPAL) ke mālama ʻia me ka chemotherapy B-ALL.
Kahi: 189 mau wahi
Hoʻoikaika ʻia a maʻamau ʻia ʻo BEP Chemotherapy i ka mālama ʻana i nā mea maʻi me nā tumors a me nā Tumor-Risk Metastatic Germ Cell Tumors.
This randomized phase III trial studies how well an accelerated schedule of bleomycin sulfate, etoposide phosphate, and cisplatin (BEP) chemotherapy works compared to the standard schedule of BEP chemotherapy in treating patients with intermediate or poor-risk germ cell tumors that have spread to other places in the body (metastatic). Drugs used in chemotherapy, such as bleomycin sulfate, etoposide phosphate, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BEP chemotherapy on a faster, or “accelerated” schedule may work better with fewer side effects in treating patients with intermediate or poor-risk metastatic germ cell tumors compared to the standard schedule.
Location: 139 locations
E hoʻohā i ka ʻōlelo hoʻohou auto-refresher